WO2023195022 - STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING ERDAFITINIB
National phase entry is expected:
Publication Number
WO/2023/195022
Publication Date
12.10.2023
International Application No.
PCT/IN2023/050335
International Filing Date
06.04.2023
Title **
[English]
STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING ERDAFITINIB
[French]
COMPOSITIONS PHARMACEUTIQUES STABLES COMPRENANT DE L'ERDAFITINIB
Applicants **
NATCO PHARMA LIMITED
Inventors
BHAVANASI, Krishna Murthy
VATTIKUTI, Satyanarayana
MUPPARAJU, Sundeep
BHAT, Pavan
NANNAPANENI, Venkaiah Chowdary
Priority Data
202241012175
07.04.2022
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2236 | |
| EPO | Filing, Examination, Granting | 12270 | |
| Japan | Filing, Examination, Granting | 2247 | |
| South Korea | Filing, Examination, Granting | 2270 | |
| USA | Filing, Examination, Granting | 5940 |
Total:
24,963
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to stable pharmaceutical compositions comprising a kinase inhibitor. More particularly, the present invention relates to stable tablet compositions comprising Erdafitinib and one or more pharmaceutically acceptable excipients and processes for preparing such compositions.[French]
La présente invention concerne des compositions pharmaceutiques stables comprenant un inhibiteur de kinase. Plus particulièrement, la présente invention concerne des compositions de comprimés stables comprenant de l'Erdafitinib et un ou plusieurs excipients pharmaceutiquement acceptables et des procédés de préparation de telles compositions.